Bioventix (BVXP)

Currency in GBP
1,970.0
0.0(0.00%)
Closed·
High dividend Yield
BVXP is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
1,955.02,000.0
52 wk Range
1,300.02,219.3
Key Statistics
Bid/Ask
1,850.00 / 2,000.00
Prev. Close
1,970
Open
1,975
Day's Range
1,955-2,000
52 wk Range
1,300-2,219.3
Volume
5.5K
Average Volume (3m)
15.87K
1-Year Change
-8.3721%
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
BVXP Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
3,900.0
Upside
+97.97%
Members' Sentiments
Bearish
Bullish
ProTips
Impressive gross profit margins

Bioventix News & Analysis

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Neutral
Technical Indicators
Sell
Moving Averages
Buy

Analyst Ratings

1 Buy
0 Hold
0 Sell
Ratings:
1 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 3,900.0
(+97.97% Upside)

Earnings

Latest Release
26/10/2026
EPS / Forecast
0.75 / --
Revenue / Forecast
6.81M / 6.34M
EPS Revisions
Last 90 days

Dividends

Payout Ratio
Payout ratio (TTM)
Earnings retained
EPS 1.46
Dividend Yield
7.61%
Industry Median 0.81%
Annualised payout
150.00
Paid unevenly
5-Years Growth
+7.39%
Growth Streak

BVXP Income Statement

Compare BVXP to Peers and Sector

Metrics to compare
BVXP
Peers
Sector
Relationship
P/E Ratio
13.5x−4.5x−0.2x
PEG Ratio
58.69−0.010.00
Price/Book
9.0x1.9x2.6x
Price / LTM Sales
7.9x4.1x2.8x
Upside (Analyst Target)
98.0%107.8%65.0%
Fair Value Upside
Unlock1.7%9.6%Unlock

Bioventix PLC creates, manufactures, and supplies sheep monoclonal antibodies (SMAs) for diagnostic applications worldwide. The company offers a portfolio of purified SMAs for thyroid, vitamin D, cardiac, drugs of abuse, fertility, oncology, and miscellaneous indications; Pyrene (HOP-G) ELISA kit, a sandwich enzyme-linked immunosorbent assay kit for the detection of 1-hydroxypyrene glucuronide in urine samples; and Pyrene (HOP-G) lateral kits, a positive read, semi-quantitative lateral flow testing system that allows for monitoring of at-risk individuals. It also provides an industrial and environmental biomonitoring platform, as well as contract SMAs services. The company was incorporated in 2003 and is based in Farnham, United Kingdom.

Ownership

Ownership Overview

Type
Common Stock Held% of Shares OutstandingMarket Value
Mutual Funds & ETFs
1.96M37.53%38.63M
Other Institutional Investors
2.01M38.39%39.51M
Public Companies & Retail Investors
1.26M24.08%24.78M
Total
5.22M100.00%102.93M

Top Holders

Holder
% of holding
Shares Held
Date Reported
Value (In 1,000s)
Gresham House Asset Management Limited12.16%635,28212,515
Liontrust Asset Management PLC9.90%517,20410,189

People Also Watch

83.00
SLPL
-0.48%
237.80
VTYV
-4.80%
805.00
KEYS
0.00%
258.20
CTEC
+0.94%

FAQ

What Is the Bioventix (BVXP) Stock Price Today?

The Bioventix stock price today is 1,970.0 GBP.

What Stock Exchange Does Bioventix Trade On?

Bioventix is listed and trades on the London Stock Exchange.

What Is the Stock Symbol for Bioventix?

The stock symbol for Bioventix is "BVXP."

Does Bioventix Pay Dividends? What’s The Current Dividend Yield?

The Bioventix dividend yield is 7.6%%.

What Is the Bioventix Market Cap?

As of today, Bioventix market cap is 102.93M GBP.

What Is Bioventix's Earnings Per Share (TTM)?

The Bioventix EPS (TTM) is 1.46.

From a Technical Analysis Perspective, Is BVXP a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Buy.

How Many Times Has Bioventix Stock Split?

Bioventix has split 0 times.

How Many Employees Does Bioventix Have?

Bioventix has 12 employees.

What is the current trading status of Bioventix (BVXP)?

As of 14/11/2026, Bioventix (BVXP) is trading at a price of 1,970.0 GBP, with a previous close of 1,970.0 GBP. The stock has fluctuated within a day range of 1,955.0 GBP to 2,000.0 GBP, while its 52-week range spans from 1,300.0 GBP to 2,219.3 GBP.

What Is Bioventix (BVXP) Price Target According to Analysts?

The average 12-month price target for Bioventix is 3,900.0 GBP, with a high estimate of 3900 GBP and a low estimate of 3900 GBP. 1 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +97.97% Upside potential.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.